Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com - Wells Fargo (NYSE:WFC) lowered its price target on Arcturus Therapeutics (NASDAQ:ARCT) to $42.00 from $45.00 on Tuesday while maintaining an Overweight rating on the stock. The biotech company, currently valued at $309 million, has shown significant price volatility with a beta of 2.26. According to InvestingPro analysis, the stock appears undervalued at current levels.
The research firm cited updated model assumptions following Arcturus’ second-quarter 2025 financial results, which showed a net loss per share of ($0.34), significantly better than the consensus estimate of ($0.89).
Wells Fargo noted that Arcturus ended the quarter with a cash position of $253.4 million, which the company indicates is sufficient to fund operations into 2028, consistent with its previous guidance.
The firm updated its earnings per share estimates for Arcturus to ($2.33) for 2025 and ($4.35) for 2026, compared to previous estimates of ($3.35) and ($4.74), respectively.
Wells Fargo expressed a favorable outlook for Arcturus ahead of next month’s cystic fibrosis (CF) data readout, citing the high proportion of CFTR null patients with no available therapy, high cumulative dose with differentiated tolerability, and expectations of greater benefit with longer-term dosing.
In other recent news, Arcturus Therapeutics reported its second-quarter 2025 financial results, which fell short of expectations. The company announced an earnings per share (EPS) of -$0.34, significantly below the anticipated $3.21, marking a negative surprise of 110.59%. Revenue for the quarter stood at $28 million, showing a decline from the previous year. These results reflect a challenging period for the company as it navigates its financial performance. Despite the earnings shortfall, the company’s stock experienced fluctuations, though specific movements were not detailed in this report. Investors are likely to watch closely how Arcturus addresses these financial challenges in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.